HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bohana-Kashtan, O. Articles by Civin, C. I. Search for Related Content PubMed PubMed Citation Articles by Bohana-Kashtan, O. Articles by Civin, C. I.

Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance

Department of Oncology, Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA

Key Words. Fas ligand (FasL) • Immune privilege • Allogeneic • Tolerance • gld • lpr • Dendritic cells

Correspondence: Curt I. Civin, M.D., Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Buntin-Blaustein Cancer Research Bldg., Room 2M44, 1650 Orleans Street, Baltimore, MD 21231 USA. Telephone: 410-955-8816; Fax: 410-955-8897; e-mail: civincu{at}jhmi.edu

The role of Fas ligand (FasL) in physiologically limiting immune responses and maintaining immune-privileged sites has led to a body of research aiming to confer protection to allogeneic grafts by expressing FasL on the allogeneic tissue or by administrating FasL-transduced donor dendritic cells. In addition, several studies have used FasL to abrogate autoimmune responses. This review presents the results of these studies and discusses the problems associated with FasL usage.

This article has been cited by other articles:

				S. B. Wallach-Dayan, R. Golan-Gerstl, and R. Breuer Evasion of myofibroblasts from immune surveillance: A mechanism for tissue fibrosis PNAS, December 18, 2007; 104(51): 20460 - 20465. [Abstract] [Full Text] [PDF]

				M. Pearl-Yafe, E. S. Yolcu, J. Stein, O. Kaplan, I. Yaniv, H. Shirwan, and N. Askenasy Fas Ligand Enhances Hematopoietic Cell Engraftment Through Abrogation of Alloimmune Responses and Nonimmunogenic Interactions Stem Cells, June 1, 2007; 25(6): 1448 - 1455. [Abstract] [Full Text] [PDF]

				N. Askenasy, E. S. Yolcu, I. Yaniv, and H. Shirwan Induction of tolerance using Fas ligand: a double-edged immunomodulator Blood, February 15, 2005; 105(4): 1396 - 1404. [Abstract] [Full Text] [PDF]